Hexagon Purus ASA: Results for the second quarter 2026

Hexagon Purus reported Q2 2026 revenue and other income of NOK 146m (-25% YoY) and EBITDA of NOK -102m (loss narrowed from NOK -161m). The company exited the quarter with firm order backlog of NOK 523m and highlighted continued progress on cost-base reductions and converting customer dialogues into orders, but balance sheet metrics remain weak (equity ratio 1%; cash NOK 308m; operating cash flow NOK -47m). With two convertible bonds outstanding (maturities in Q1 2028 and Q1 2029) and ongoing evaluation of structural capital measures, management guided that the H2 2026 setup is improved versus a year ago, though the operating environment remains demanding.

Analysis

The key read-through is that the equity is now a financing optionality story more than an operating story. The lower EBITDA loss matters mainly because it delays the cash crunch, but with equity essentially wiped out, common holders are still behind the convert stack and any real value recovery depends on a credible capital-structure solution, not just incremental cost cuts.

The backlog figure looks supportive on the surface, but the market should discount it heavily because order conversion in hydrogen hardware has been erratic and lumpy. The bigger second-order effect is that customers and channel partners will likely demand more balance-sheet comfort, which can slow deal conversion further and push procurement toward better-capitalized competitors in the hydrogen and e-mobility supply chain.

Time horizon matters: the immediate post-print move can be a relief rally on lower burn, but the 1-3 month catalyst path is dominated by convert negotiations, refinancing terms, or a dilutive recapitalization. Over 6-18 months, the stock only works if management can prove that the lower cost base is matched by durable order inflow; otherwise the business may simply be shrinking into its liabilities. The contrarian angle is that consensus may be underestimating how quickly a bad capital-structure outcome can erase any operating progress.

What would falsify the bearish setup is a non-dilutive financing package, a meaningful step-up in firm orders, or an explicit guidance bridge to EBITDA breakeven without another equity raise. Absent that, the current setup still looks like a low-float distress name where creditors and convert holders have better positioning than common equity.

Key Decisions for Investors

• Short HPURF on post-earnings strength over the next 1-3 months; thesis is that the market will refocus from cost reduction to refinancing/dilution risk. Cover if management announces a materially non-dilutive convert solution or strategic equity partner.
• If borrow is available, pair long NEL/BLDP versus short HPURF for a 1-3 month relative-value trade; HPURF has the weakest balance sheet in the hydrogen basket, so any sector rebound should favor better-capitalized peers first. Falsify if HPURF secures an external capital injection on acceptable terms.
• Do not buy the equity for the backlog alone; wait for the Q3 balance-sheet actions. The risk/reward remains unfavorable unless backlog converts into sustained revenue acceleration and the cash burn drops below the current run-rate by at least 30-40%.
• Set an alert around any disclosed convertible-bond exchange or rights issue terms: a punitive restructuring likely implies another leg down, while a clean maturity extension without equity issuance would force a reassessment.